Atlas Trials

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Clinical trial NCT04840784 · TERMINATED

Trial details

NCT number
NCT04840784
Sponsor
Shengke Pharmaceuticals Pty Ltd
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
NHLLeukemia
Start date
2021-06-29
Primary completion
2023-05-02
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.